Commentary: Patient Cost Sharing and Medical Expenditures for the Elderly by Mihajlo Jakovljevic
GENERAL COMMENTARY
published: 30 March 2016
doi: 10.3389/fphar.2016.00073
Frontiers in Pharmacology | www.frontiersin.org 1 March 2016 | Volume 7 | Article 73
Edited by:
Iñaki Gutiérrez-Ibarluzea,
OSTEBA, Basque Office for HTA,
Spain
Reviewed by:
Brian Godman,
Karolinska Institutet, Sweden
*Correspondence:
Mihajlo (Michael) Jakovljevic
sidartagothama@gmail.com;
jakovljevicm@medf.kg.ac.rs
Specialty section:
This article was submitted to
Pharmaceutical Medicine and
Outcomes Research,
a section of the journal
Frontiers in Pharmacology
Received: 07 January 2016
Accepted: 10 March 2016
Published:
Citation:
Jakovljevic M (2016) Commentary:
Patient Cost Sharing and Medical
Expenditures for the Elderly.
Front. Pharmacol. 7:73.
doi: 10.3389/fphar.2016.00073
Commentary: Patient Cost Sharing
and Medical Expenditures for the
Elderly
Mihajlo (Michael) Jakovljevic *
Graduate Health Economics and Pharmacoeconomics Curricula, Faculty of Medical Sciences, University of Kragujevac,
Kragujevac, Serbia
Keywords: cost sharing, medical expenditure, elderly, Japan, population aging
A commentary on
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Fukushima et al. recently published research on the relationship between cost sharing policies and
medical spending by the elderly (Fukushima et al., 2016). Japan, as the nation in the most advanced
stage of population aging, is indeed the best place to search for answers (Ogura et al., 2007). The
authors provided us with a valuable contribution on the effects of such policies on the demand
for medical services and costs within the subpopulation of senior citizens. The study has been
conducted within a sound methodological framework and significantly expands our knowledge
on the oldest among the world’s large nations. I would like to complement their revealing findings
with few additional facts crucial for understanding these issues.
One of the baseline results of the study claims: “lower cost sharing significantly increasesmedical
spending.” This actually follows the natural logic that a patient is likely to consumemore care if it is
effectively free at the point of usage. Three decades ago policy makers believed it should be possible
for a cost sharing mechanism to contain costs and induce net savings (Keeler and Rolph, 1983). It
appears that the final balance is highly dependent on prevailing governing practices and legislative
framework within the observedmarket (Remler and Glied, 2006). Besides there are studies showing
that increased co-payments—especially for pharmaceuticals—have a detrimental effect on access
and compliance—potentially leading to worse health outcomes (Shrank et al., 2006; Roberts et al.,
2012a,b; Maimaris et al., 2013; Barnieh et al., 2014; Putrik et al., 2014; Simoens and Sinnaeve, 2014;
Barbui and Conti, 2015; Tefferi et al., 2015). There are findings from Greece where major increases
in patient co-payments were coupled with a reduction in public services in areas such as infection
and mental health. This national case also adds to the literature (Ayuso-Mateos et al., 2013; Siskou
et al., 2013; Kentikelenis et al., 2014). However, the impact of increased co-payments on health is
still subject to ongoing debate (Mann et al., 2014). WHO had serious concerns on accessibility and
co-payment. Therefore, it settled on a target of 80% availability for affordable essential medicines,
including generics. Targeted therapeutic areas were major Non-Communicable Diseases (NCDs),
such as diabetes and hypertension. This policy aimed to address global concerns with the impact of
NCDs on morbidity and mortality1.
The article conveys an important message with regards to the role of cost sharing in prescribing
and dispensing medicines (Johnson et al., 1997). The authors noticed the concerning fact that
1Global Action Plan for the Prevention and Control of Noncommunicable Diseases 2013–2020.
http://www.who.int/nmh/events/2013/revised_draft_ncd_action_plan.pdf?ua=1 (updated revised draft).
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reduced cost sharing after the age of 70 increases demand for
brand-name medicines, unlike generics. This change ultimately
leads to an expanding market share of original drug dispensing
and sales. The roots of this change could be found in consumer
behavior. There is traditionally a strong lack of confidence in
the quality of copycat medicines attributed to the Japanese
patient (Kobayashi et al., 2011). This explains the willingness
to pay slightly more for an original drug compared to generic
alternative in a reduced cost-sharing setting. The uniqueness
of the Japanese pharmaceutical market and its global impact
refers to its mammoth size (World’s second largest) and the
smallest share of generics compared to other major high-income
OECD economies (Penner-Hahn and Shaver, 2005). National
efforts to increase generic replacement of brand name drugs have
long been a source of public debate among Japanese authorities
(Jakovljevic et al., 2014). The surprising findings of Fukushima
et al. appropriately indicate the need for differential cost sharing
rates as a strategy to contain drug acquisition costs in future.
There is a variety of measures used to increase the
prescribing of generics vs. originators in Europe. These include
compulsory substitution, e.g., in Sweden (Andersson et al., 2005),
compulsory INN prescribing, e.g., in Lithuania (Garuoliene
et al., 2011), or high voluntary INN prescribing as in the
UK (Godman et al., 2013). The high use of generics should
not be troubled conditional to guaranteed quality. Some of
these historical experiences might be applicable to Japanese
policy challenges as well. We should be aware that a general
provision of guidelines has limited impact visible in the
demise of the RMO guidelines in France for GPs (Sermet
et al., 2010). The comprehensive approach to instigating a
limited list of well-proven medicines, coupled with simple
advice, has worked well in Stockholm, Sweden. It leads to
improved care through consistency in use of well-proven
medicines as well as reduced pharmaceutical expenditure
(Gustafsson et al., 2011).
The phenomenon of a shrinking labor force and threatened
financial sustainability of health care provision was recognized
in the Japanese market a few decades ago (Ogura, 1994). The
development of policies aimed atmeeting this challenge followed,
with diverse success rates (Tsutsui and Muramatsu, 2007;
Campbell, 2014). It has clearly been proven that the long term
health expenditure pattern follows the pace of population aging
(Stojkovic and Milovanovic, 2015). Outsourcing from Japanese
regression discontinuity study there are valuable lessons with
implications for other world regions. Nations of the European
region age rapidly while key consequences for the national health
sectors and economies are yet to be seen (Jakovljevic M. 2015).
The pace of the process remains uneven but surprisingly, involves
some of the traditional young nations historically famous for
their high fertility rates (Jakovljevic and Laaser, 2015). Appliance
of cost sharing approaches as a strategy to contain medical costs
has become prominently popular even among Eastern European
countries (Tambor et al., 2015). Administration of cost sharing as
demand side intervention to limit medical consumption among
the elderly is clearly beneficial for the society. There remain
two essential issues likely to spark further professional debate
coming from opposite angles of different stakeholders. Patient
perspective focuses on how to protect senior citizens from
vulnerabilities outsourcing from such policies. These citizens face
falling household income after retirement and lower affordability
of medicines and medical services (Miralles and Kimberlin,
1998). Such financial burden is lessened by generous provision
of cost sharing after the age of 70 provided in Japanese
health system. Another issue comes from the perspective of the
society. How to limit the heavy burden of medical expenditure
attributable to the elderly within the existing financial constraints
of a large aging nation? (Ogura and Jakovljevic, 2014) Strategies
complementing the evident success of cost sharing will be
sought in the upcoming decades as expenditure continues to
grow further (Jakovljevic M. M. 2016). The advanced stage of
Japanese social care for the elderly shall probably remain a prime
example of the rapidly evolving health systems of the Asia-Pacific
region.
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